1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Pharnext
  6. News
  7. Summary
    ALPHA   FR0011191287


Real-time Euronext Paris  -  05/24 08:55:37 am EDT
0.0110 EUR   -5.98%
05/16New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time
05/16De nouvelles données de l'essai en ouvert PLEO-CMT-FU montrent un bénéfice durable de PXT3003 chez les patients atteints de la maladie de Charcot-Marie-Tooth de type 1A après une durée totale de cinq ans d'essai clinique
05/16De nouvelles données de l'essai en ouvert PLEO-CMT-FU montrent un bénéfice durable de PXT3003 chez les patients atteints de la maladie de Charcot-Marie-Tooth de type 1A après une durée totale de cinq ans d'essai clinique
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Pharnext : Présentation Corporate de Pharnext

01/03/2022 | 05:49am EDT



Janvier 2022



References herein to this presentation (the "Presentation") shall mean and include this document, any oral presentation accompanying this document provided by Pharnext SA (the "Company") and any further information that may be made available in connection with the subject matter contained herein.

By viewing or receiving or reading this Presentation or attending any meeting where this Presentation is made, you agree to be bound by the limitations, qualifications and restrictions set out below:

This Presentation is confidential, is intended for the recipient only and thus may not be forwarded, reproduced, redistributed or passed to any other person or published in whole or in part for any purpose. If this document has been received in error, it must be returned immediately to the Company. By receiving this Presentation, you become bound by the above-referred confidentiality obligation. Failure to comply with such confidentiality obligation may result in civil, administrative or criminal liabilities.

Recipients of the Presentation should not deal or encourage any other person to deal in the securities of the Company.

This Presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, transmission, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

No securities of the Company have been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or under any state securities laws, and the securities of the Company may not be offered or sold in the United States (or to, or for the account or benefit of U.S. Persons) except pursuant to an exemption from, or a transaction not subject to, the registration requirements of the U.S. Securities Act. The Company has no current intention to register in the United States any portion of its securities or to conduct a public offering of any of its securities in the United States.

No action has been undertaken or will be undertaken to make an offer to the public of securities requiring a publication of a prospectus in the United Kingdom or any member State of the European Economic Area (each a "Relevant State"). As a result, the securities may not and will not be offered in any Member State, except pursuant to Article 1(4) or Article 3(2) of Regulation (EU) 2017/1129 of June 14, 2017 (the "Prospectus Regulation") or under other circumstances not requiring the Company to publish a prospectus pursuant to the Prospectus Regulation and/or the applicable regulations in such Relevant States. For the purposes of this paragraph, "securities offered to the public" in a given Relevant State means a communication to any persons, in any form and by any means, presenting sufficient information on the terms of the offer and the securities to be offered, so as to enable an investor to decide to purchase or subscribe for those securities, as the same may be varied in that Relevant State.

This Presentation has been prepared by the Company and is for information only. This document does not purport to contain comprehensive or complete information about the Company and is qualified in its entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on Euronext Growth Paris, including, in particular, the risk factors set out in the Company's annual management report to the shareholders, and in any other periodic report, which are available free of charge on the website of the Company (www.pharnext.fr). Information and other data appearing in such publications, and certain figures and numbers appearing in this document have been rounded. Consequently, the total amounts and percentages appearing in tables and elsewhere may not necessarily equal the sum of the individually rounded figures, amounts or percentages.

No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this Presentation, or its use for any purpose, and no reliance should be placed on any information or opinions contained herein. The Company, its subsidiaries, its advisors and representatives accept no responsibility for and shall not, under any circumstance, be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained in it. In particular, this document contains information on the Company's markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company's own estimates which may not be accurate and thus no reliance should be placed on such information. Any prospective investors must make their own investigation and assessments and consult with their own advisors concerning any evaluation of the Company and its prospects, and this document, or any part of it, may not form the basis of or be relied on in connection with any contact, commitment or investment decision.

The information and opinions contained in this document are provided as of the date of this document only and may be updated, supplemented, revised or amended, and thus such information is subject to change at any time. Neither the Company, nor its advisors, nor any other person is under any obligation to update the information, statements or opinions contained in this document.

All statements in the Presentation other than statements of historical fact are or may be deemed to be forward-looking statements. These forward-looking statements are not guarantees of future performance and involve a number of known and unknown risks and uncertainties. These risks and uncertainties, and other factors, could adversely affect the outcome of the forward- looking statements, and actual results could differ materially from those contemplated in the statements. As a result, you are cautioned not to rely on such forward-looking statements. Forward-looking statements speak only as of the date of this document and the Company expressly disclaims any obligation or undertaking to update or re-issue any forward-looking statements contained in this Presentation.

Especially in the context of the current health crisis, these risks and uncertainties, include among other things, the uncertainties inherent in research and development of new products, including future clinical trial results and analysis of clinical data (including post marketing data), decisions by regulatory authorities, such as the Food and Drug Admnistration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product and candidates, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates.


1. Pharnext


Management Team with Proven Track Record


Dr. David Horn Solomon

Dr. Burkhard Blank

Xavier Paoli, MSc

Chief Executive Officer

Chief Medical Officer

Chief Operating Officer



Pharnext is a

late clinical stage

biopharmaceutical company focused on

advancing innovative PleotherapyTM

drug candidates in diseases with

high unmet need,including PXT3003 in Phase 3 for Charcot-Marie-Tooth Disease Type 1A

Pour lire la suite de ce noodl, vous pouvez consulter la version originale ici.


Pharnext SA published this content on 03 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 January 2022 10:48:07 UTC.

© Publicnow 2022
All news about PHARNEXT
05/16New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in ..
05/16De nouvelles données de l'essai en ouvert PLEO-CMT-FU montrent un bénéfice durable de P..
05/16De nouvelles données de l'essai en ouvert PLEO-CMT-FU montrent un bénéfice durable de P..
05/16New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in ..
05/16Pharnext Announces New Results from the Ongoing Open-Label Follow-Up Extension Study of..
05/05PHARNEXT : The Latest Findings From CMT&Me, a ?Real-World? Digital Lifestyle Study on Char..
04/25PHARNEXT : Présentation Corporate de Pharnext
04/25PHARNEXT : Pharnext Reports Full Year 2021 Financial Results and Recent Business Updates
04/25PHARNEXT : Annual results
03/31Pharnext's Chair Quits; Names Interim Successor
More news
Sales 2021 3,59 M 3,84 M 3,84 M
Net income 2021 -26,0 M -27,8 M -27,8 M
Net cash 2021 6,83 M 7,30 M 7,30 M
P/E ratio 2021 -0,02x
Yield 2021 -
Capitalization 0,25 M 0,27 M 0,27 M
EV / Sales 2021 -1,83x
EV / Sales 2022 1,71x
Nbr of Employees -
Free-Float 49,7%
Duration : Period :
Pharnext Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHARNEXT
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 0,01 €
Average target price 2,50 €
Spread / Average Target 21 268%
EPS Revisions
Managers and Directors
David Horn Solomon Chief Executive Officer & Director
Valérie Worrall Chief Financial Officer
Joshua Schafer Chairman
Philippe Rinaudo Chief Data Science Officer
Burkhard Blank Chief Medical Officer, Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.89%472 179
PFIZER, INC.-10.45%296 704
ROCHE HOLDING AG-14.40%273 052
ABBVIE INC.9.33%261 585